Nutex Health, Inc. (NUTX) P/E Ratio History
Premium ValuationTrading at 20.7x vs 5Y avg 15.2x · 88th percentile · Premium to historical baseline · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, Nutex Health, Inc. (NUTX) trades at a price-to-earnings ratio of 20.7x, with a stock price of $216.50 and trailing twelve-month earnings per share of $25.07.
The current P/E is 36% above its 5-year average of 15.2x. Over the past five years, NUTX's P/E has ranged from a low of 3.4x to a high of 62.2x, placing the current valuation at the 88th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, NUTX is roughly in line with its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, NUTX trades roughly in line with the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NUTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NUTX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NUTX P/E vs Peers
Care Delivery Networks and Value-Based Care peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 21.4 | 1.06 | +23% | |
| $441M | 9.6 | - | -15% | |
| $11B | 7.6 | 0.47Best | +37% | |
| $22B | 16.7 | 0.51 | -53% | |
| $384M | 0.7Lowest | - | +197% | |
| $92B | 15.0 | 0.72 | +29% | |
| $1B | 59.0 | - | -23% | |
| $108B | 23.5 | - | +49% | |
| $53B | 31.6 | - | +325%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NUTX Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $170.89 | $25.07 | 6.8x | -55% |
| FY2026 Q1 | - | $95.04 | $12.88 | 7.4x | -52% |
| FY2025 Q4 | Dec 31 2025 | $164.62 | $8.92 | 18.5x | +21% |
| FY2025 Q3 | - | $103.32 | $18.42 | 5.6x | -63% |
| FY2025 Q2 | Jun 30 2025 | $124.49 | $8.94 | 13.9x | -8% |
| FY2025 Q1 | Mar 31 2025 | $47.03 | $11.89 | 4.0x | -74% |
| FY2024 Q4 | - | $31.69 | $9.25 | 3.4x | -77% |
| FY2022 Q2 | - | $483.75 | $7.78 | 62.2x | +309% |
Average P/E for displayed period: 15.2x
NUTX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NUTX — Frequently Asked Questions
Quick answers to the most common questions about buying NUTX stock.
What is NUTX's P/E ratio?
Nutex Health, Inc. (NUTX) trailing twelve-month P/E ratio is 20.7x, based on TTM diluted EPS of $25.07. The 5-year average P/E is 15.2x and the historical range spans 3.4x to 62.2x.
Is NUTX stock overvalued or undervalued?
NUTX trades at 20.7x P/E, above its 5-year average of 15.2x. The 88th percentile ranking within the 3.4x–62.2x historical range indicates a premium to historical valuation.
Is NUTX stock expensive?
Yes, NUTX is expensive relative to its own history. The current P/E of 20.7x is above the 5-year average of 15.2x. The stock sits at the 88th percentile of its 5-year valuation range.
What is NUTX's historical P/E range?
Over the past 5 years, NUTX's P/E ratio has ranged from 3.4x to 62.2x, with a median of 7.4x and an average of 15.2x. The current P/E of 20.7x places the stock at the 88th percentile of this range. Full historical data spans 2022–2026.
How does NUTX's P/E compare to the S&P 500?
NUTX trades at 20.7x P/E versus the S&P 500 median of 24.5x. The 16% discount to the market suggests lower growth expectations or perceived higher risk.
How does NUTX's valuation compare to Healthcare peers?
Nutex Health, Inc. P/E of 20.7x compares to the Healthcare sector median of 23.2x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NUTX's PEG ratio?
NUTX PEG ratio is N/A, based on a P/E of 20.7x and EPS growth of 7.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NUTX's earnings yield?
NUTX earnings yield is 4.84%, the inverse of its 20.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.